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Abstract
Background: This study determined macrolide resistance genotypes in clinical isolates of Streptococcus
pneumoniae from multiple medical centers in Lebanon and assessed the serotype distribution in relation to these
mechanism(s) of resistance and the source of isolate recovery.
Methods: Forty four macrolide resistant and 21 macrolide susceptible S. pneumoniae clinical isolates were tested
for antimicrobial susceptibility according to CLSI guidelines (2008) and underwent molecular characterization.
Serotyping of these isolates was performed by Multiplex PCR-based serotype deduction using CDC protocols. PCR
amplification of macrolide resistant erm (encoding methylase) and mef (encoding macrolide efflux pump protein)
genes was carried out.
Results: Among 44 isolates resistant to erythromycin, 35 were resistant to penicillin and 18 to ceftriaxone.
Examination of 44 macrolide resistant isolates by PCR showed that 16 isolates harbored the erm(B) gene, 8 isolates
harbored the mef gene, and 14 isolates harbored both the erm(B) and mef genes. There was no amplification by
PCR of the erm(B) or mef genes in 6 isolates. Seven different capsular serotypes 2, 9V/9A,12F, 14,19A, 19F, and 23,
were detected by multiplex PCR serotype deduction in 35 of 44 macrolide resistant isolates, with 19F being the
most prevalent serotype. With the exception of serotype 2, all serotypes were invasive. Isolates belonging to the
invasive serotypes 14 and 19F harbored both erm(B) and mef genes. Nine of the 44 macrolide resistant isolates
were non-serotypable by our protocols.
Conclusion: Macrolide resistance in S. pneumoniae in Lebanon is mainly through target site modification but is also
mediated through efflux pumps, with serotype 19F having dual resistance and being the most prevalent and invasive.
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Background
Streptococcus pneumoniae continues to be a major cause
of morbidity and mortality in humans. It is one of the
most significant bacterial pathogens causing community
acquired infections, most notably pneumonia, otitis
media, bacteremia, and meningitis [1,2]. Treatment of
pneumococcal infections is becoming difficult due to
the high prevalence of penicillin-resistant strains and to
the rapid development of resistance to other antimicro-
bials including macrolides. These drugs are extensively
used for the treatment of respiratory infections due to
their broad-spectrum of activity and safety profile.
Although macrolide resistance varies geographically, it is
widely spread all over the globe [3-6].
Macrolide resistance in S. pneumoniae is primarily due
to two mechanisms; target site modification and efflux
pump expulsion. Target site modification is encoded by
the erm(B) gene which leads to reduction in the binding
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This mechanism relies on methylation of specific adenine
residues (A2058) in 23S rRNA by the methylase-product
of the erm gene leading to cross resistance to macrolides,
lincosamides, and streptogramins. Therefore, isolates
harboring the erm gene have the MLSb (resistance to
macrolides, lincosamides, and streptogramins) phenotype
[7,8]. While isolates harboring the erm gene are resistant
to all macrolides, isolates expressing an efflux pump
encoded by the mef gene are resistant to only 14 and 15-
membered macrolides. Isolates harboring the mef gene
have the M (resistance to macrolides) phenotype [9,10].
National and regional data about serotype distribution
has been very useful in vaccine introduction. The use of
the seven-valent pneumococcal conjugate vaccine (PCV7)
resulted in a dramatic decline in invasive pneumococcal
disease in children. More recently however, a 10-valent
(PCV10) and 13-valent vaccine (PCV13) were introduced
after increasing reports of non-PCV7 serotypes [11,12].
Therefore, ongoing serotype surveillance is essential for
evaluation of the impact and the suitability of available
vaccines and their coverage in different geographic loca-
tions. Vaccination with protein-conjugated vaccines is also
important in preventing the spread of vaccine-type, anti-
biotic-resistant strains due to its ability to significantly
decrease nasopharyngeal colonization in vaccinated
children [2].
Since macrolide resistance is being encountered at dif-
ferent medical centers in Lebanon, this study was war-
ranted to: 1) determine the macrolide resistance genotypes
among S. pneumoniae clinical isolates collected from med-
ical centers in Lebanon, and to 2) assess the serotype dis-
tribution among these isolates in relation to the
mechanism(s) of resistance and invasiveness of the
isolates.
Methods
Source and Identification of S. pneumoniae Isolates
Sixty five S. pneumoniae isolates were collected from var-
ious clinical specimens including blood, sputum, bronchial
wash, cerebrospinal fluid, deep tracheal aspirate, pleural
fluid and other sites. Isolates were collected prospectively
from various medical centers in Lebanon during the speci-
fied period of 2008 and 2010. Preliminary susceptibility
testing and phenotypic identification was performed at the
enrolled medical center laboratories. Subsequently, the
samples were forwarded to the clinical microbiology lab at
AUBMC for further characterization. Those samples
determined as erythromycin resistant, and those also col-
lected and determined at the clinical microbiology labora-
tory as erythromycin sensitive (2008 CLSI guidelines) were
coded and sent to the centralized lab at the Department of
Experimental Pathology, Microbiology and Immunology at
AUB for the MSc student candidate to work on blindly
[13].
Antimicrobial Susceptibility Testing
All isolates were tested against erythromycin, tetracy-
cline, trimethoprim-sulfamethoxazole and chlorampheni-
col by disc diffusion method according to the 2008
Clinical Laboratory Standards Institute (CLSI) guidelines.
In addition, isolates resistant to erythromycin were
further tested for susceptibility to penicillin and ceftriax-
one by E-tests and results were interpreted according to
the 2008 CLSI guidelines. For non-meningitis isolates an
MIC ≥ 8 μg/ml for penicillin and an MIC ≥ 4 μg/ml for
ceftriaxone was considered resistant. For meningitis iso-
lates an MIC ≥ 0.12 μg/ml for penicillin and an MIC ≥
2 μg/ml for ceftriaxone was considered resistant. Sus-
ceptibility testing was monitored by using a quality con-
trol strain (S. pneumoniae ATCC 49619) in the test runs
and was verified based on the CLSI-QC breakpoint limits
for this strain [14].
Detection of Erythromycin Resistance Genes
Total DNA was extracted from all isolates using the Illus-
tra Bacteria Genomic Prep Mini Spin Kit (GE, Healthcare,
UK). Polymerase chain reactions were used to amplify two
macrolide resistancee n c o d i n gg e n e s :erm(B) and mef
using specific primers [15]. PCR mix consisted of 1 μMo f
each primer, 1× Taq buffer, 1.25 U Taq DNA polymerase,
2.0 mM of MgCl2, 0.05 mM of deoxynucleoside tripho-
sphate (dNTP), and 29.25 μl nanopure water. A thermal
cycler (Bio-Rad, C-1000, USA) was used for amplification
with PCR conditions as described by Sutcliffe et al [16]. A
reference CDC S. pneumoniae strain harboring both the
erm(B) and mef genes was used as a positive control for
the PCR reactions.
Capsular Multiplex PCR Serotype Deduction
Capsular serotyping was done by a multiplex PCR assay
[17]. A total of 41 primer pairs were used and grouped
into seven multiplex reactions based on serotype distri-
butions among invasive pneumococci recovered by the
United States Centers for Disease Control & Prevention
[17]. Forty three CDC S. pneumoniae isolates with
known serotypes were used as positive controls. Each
reaction included a set of primers targeting different ser-
otype specific sequences in addition to an internal posi-
tive control for a conserved region in the pneumococcal
cps operon. Multiplex PCR serotype deduction was per-
formed using the method described by Pai et al. [17]. Ser-
otypes obtained at our lab were confirmed by both
classical capsular methods and multiplex PCR at the Uni-
ted States Naval Medical Research Unit #3 in Cairo,
Egypt.
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Antimicrobial Susceptibility
Forty four (67.7%) S. pneumoniae isolates were resistant to
and 21 (32.3%) were susceptible to erythromycin. Suscept-
ibility profiles of S. pneumoniae isolates to chloramphenicol
(C), trimethoprim-sulfamethoxazole (SXT), and tetracy-
cline (TE) are shown in Table 1. In addition, the percent
susceptibility to ceftriaxone and penicillin among these iso-
lates was 59.09% (n = 26) and 20.45% (n = 9) respectively.
Fourteen of 44 isolates (31.81%) exhibited resistance to
penicillin, whereas 21 of 44 isolates (47.72%) exhibited
intermediate resistance to penicillin. As for ceftriaxone, 5
of 44 (11.36%) isolates were found to be resistant and 13 of
44 (29.55%) were of intermediate resistance (Table 1).
PCR Amplification of Resistance Genes
PCR amplification of the resistance encoding genes tested
showed that the erm(B) and mef genes were present in
1 6 / 4 4( 3 6 % )a n d8 / 4 4( 1 8 % )o fS. pneumoniae isolates
resistant to erythromycin, respectively. Fourteen of 44
(32%) isolates harbored both genes. Neither erm(B) nor
mef were detected in 6/44 (14%) of the macrolide resistant
isolates (Figure 1). Also, neither gene was detected in the
control S. pneumoniae macrolide susceptible isolates.
Multiplex PCR-Based Serotype Deduction
The resistant isolates belonged to seven different capsular
serotypes: 19F (31.8%), 23 (13.6%), 2 (11.3%), 14 (9%),
19A (6.8%), 12F (4.5%), and 9V/9A (2.7%) in 35 of 44
(79.5%) isolates. Nine of the 44 isolates (20.4%) were not
serotypable by our protocols. Among the 21 erythromy-
cin susceptible isolates, 9 different serotypes were
detected with 4 isolates belonging to serotype 5, 3 isolates
to serotype 9V/9A, 2 isolatest os e r o t y p e6 A / B / C ,3i s o -
lates to serotype 2, and one isolate each to serotypes
15B/15C, 4, 21, 38, and 35 (Table 2).
Discussion
This study demonstrated that two mechanisms are
involved in macrolide resistance among S. pneumoniae
isolates from Lebanon, namely, efflux pump mediated
resistance and ribosomal modification due to adenine-
dimethylase, with dominance of the latter. This observa-
tion is not concordant with that seen in some European
countries like France, Spain, and Poland where macro-
lide resistance due to efflux pumps is almost exclusive
[18]. This mechanism is also mostly prevalent in the
USA and some other European countries like Greece
and Germany [18,19]. Moreover, a high rate of dual
resistance was detected in our isolates where 14 of 44
(32%) of the isolates carried both genes.
Some of our clinical isolates were found to be both
erm(B) and mef negative, suggesting the possibility of
one of the newly described resistance mechanisms, such
as mutations in the 23S rRNA or alteration of the ribo-
somal proteins L4 and L22 [20,21] requiring further
investigation. The high (79.5%) prevalence rate of peni-
cillin resistance among our erythromycin resistant iso-
lates denotes that in our community, the evolution of
erythromycin resistance is driven, possibly by the spread
of penicillin resistant clones since isolates with the same
serotypes manifested resistance to both penicillin and
macrolides. Moreover, the high rate of macrolide resis-
tance was accompanied by a high rate of tetracycline
resistance (77%) indicating a possible association to the
conjugative transposon Tn1545 that confers resistance
to tetracycline via the tet(M) gene in addition to resis-
tance to macrolides [22].
There is increasing evidence that macrolide resistance
may result in clinical failure. Studies worldwide have
shown that the frequency of this resistance might be
related to the level of macrolide consumption [23,24].
The same rationale may apply to Lebanon where over-
use of macrolides may contribute to the observed
increase in resistance to these antimicrobial agents in S.
pneumoniae.
As already mentioned, the majority of macrolide resis-
tant isolates in our community belonged to seven differ-
ent serotypes: 19F, 23, 2, 14, 19A, 12F, and 9V/9A. These
results are concordant with the most common serotypes
Table 1 Antimicrobial susceptibility profiles for 44 macrolide resistant S. pneumoniae isolates by disk diffusion or
E-test
Number & Percentage of Isolates
Antimicrobial test Susceptible Intermediate Resistant
Disk Diffusion
Chloramphenicol (C) n = 43 (97.72%) n = 0 (0%) n = 1 (2.27%)
Sulfamethoxazole-Trimethoprim (SXT) n = 12 (27.27%) n = 1 (2.27%) n = 31 (70.45%)
Tetracycline (TE) n = 10 (22.72%) n = 1 (2.27%) n = 33 (75%)
E-test
Penicillin (PG) n = 9 (20.45%) n = 21 (47.73%) n = 14 (31.82%)
Ceftriaxone (TX) n = 26 (59.09%) n = 13 (29.55%) n = 5 (11.36%)
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otypes of isolates recovered from invasive pneumococcal
infection cases were 19F, 14, 23, 19A, 9V/9A, and 12F
with serotype 19F being the most common. Nine of 14
(64.28%) isolates carrying both the resistance genes were
serotype 19F (Table 3). This might suggest that isolates
belonging to serotype 19F are highly resistant to macro-
lides. In addition, the serotypes 12F and 14 were asso-
ciated with both dual resistance and invasiveness.
Serotype 2, one of the most prevalent serotypes, seems to
be non-invasive since it was found among the upper and
lower respiratory tract specimens, but not among speci-
mens from sterile sites.
It is noteworthy that the pool of serotypes found
among macrolide resistant isolates was completely differ-
ent from the pool of serotypes found for susceptible iso-
lates with the exception of serotype 9V/9A which was
common among macrolide resistant and macrolide sus-
ceptible isolates. Interestingly, serotype 19F, which was
the major serotype found among resistant and invasive
isolates, was not found among the susceptible ones. This
Figure1 Percentage of gene distribution among macrolide resistant S. pneumoniae isolates (n = 44). erm: erythromycin resistance
methylase, mef: macrolide efflux pump, ND: not determined.
Table 2 Serotype distribution among macrolide susceptible (n = 21) and macrolide resistant (n = 44) S. pneumoniae
isolates
Serotype Macrolide Resistant Isolates Macrolide Susceptible Isolates
19F 31.8% -
23 13.6% -
2 11.3% 14.28%
14 9% -
19A 4.5% -
12F 2.7% -
9V/9A - 14.28%
5 - 19.04%
6A/B/C - 9.5%
15B/C - 4.76%
4 - 4.76%
21 - 4.76%
38 - 4.76%
35 - 4.76%
No serotype detected 20.45% 19.04%
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macrolide resistance among our S. pneumoniae isolates.
Alarmingly, some of the most prevalent macrolide
resistant serotypes recovered, including serotypes 2 and
12, are not covered by PCV7, PCV10 or PCV13 vaccines
[12] and thus, constitute a risk for dissemination in the
community. Notably the remaining macrolide resistant
serotypes that were recovered are covered by PCV-7,
PCV-10 and/or PCV-13, including the highly prevalent
serotypes 19F, 23 and 14 [12]. In Lebanon, pneumococ-
cal conjugate vaccines are available in the private sector
b u ta r en o ti n c l u d e di nt h eE x p a n d e dP r o g r a mo f
Immunization. The estimated PCV vaccine coverage is
10-15% for children under 5 years of age. Most of our
isolates with PCV covered serotypes were obtained from
unvaccinated subjects.
In conclusion, though the macrolide resistance
observed in our S. pneumoniae isolates is mostly due to
target site modification by the methylase encoded by the
erm(B) gene, many isolates also demonstrated efflux
pump mediated resistance to macrolides. Moreover, a
number of isolates were invasive and macrolide resis-
tant, with only a few belonging to serotypes covered by
currently available vaccines. Understanding the mechan-
isms of resistance to macrolides may be helpful in
choosing the correct treatment regimen in certain situa-
tions but is definitely important in the development of
new antimicrobial agents. Moreover, continued surveil-
lance for changes in serotype distribution is necessary,
especially after the introduction of new vaccines.
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